Has the FDA Approved Lurbinectedin for Ovarian Cancer?
No, the FDA has not approved lurbinectedin (Zepzelca) specifically for ovarian cancer. Its sole FDA approval is for metastatic small cell lung cancer (SCLC) in adults with disease progression on or after platinum-based chemotherapy, granted via accelerated approval in June 2020.[1]
What Is Lurbinectedin Approved For?
Lurbinectedin targets the oncogenic transcription process and is administered intravenously. The SCLC approval relies on overall response rate and duration of response from the phase 2 PMDX-17-003 trial, with ongoing confirmation via the phase 3 ATLANTIS trial.[1][2] No other solid tumor indications have full FDA approval.
Is Lurbinectedin Used Off-Label for Ovarian Cancer?
Off-label use occurs in clinical practice for platinum-resistant ovarian cancer, based on preclinical data showing activity in homologous recombination repair-deficient models. Retrospective studies report response rates around 20-30% in heavily pretreated patients, but these lack prospective validation.[3]
What Ovarian Cancer Trials Involve Lurbinectedin?
Ongoing phase 2 and 3 trials explore combinations:
- Lurbinectedin + doxorubicin or irinotecan for recurrent ovarian cancer (NCT02454972, NCT03367403).
- Lurbinectedin + pembrolizumab in platinum-resistant cases (NCT04171700).
Early data suggest 25-35% response rates, but no results support approval yet.[4] Avelumab maintenance approval (2021) sets a benchmark for PARP inhibitor failures in ovarian cancer.[5]
Why Pursue Lurbinectedin in Ovarian Cancer?
Ovarian cancer patients post-platinum often face limited options like bevacizumab or mirvetamib. Lurbinectedin's DNA damage mechanism complements PARP inhibitors, filling gaps in BRCA-mutated or HRD-positive subsets.[3] PharmaMar holds patents until ~2031; no generics expected soon.[6]
When Might Approval Happen?
No pending FDA applications for ovarian cancer. Priority review could follow positive phase 3 data by 2025-2026, but accelerated approval risks withdrawal if confirmatory trials fail, as seen in SCLC label updates.[2]
Sources:
[1] FDA.gov - Lurbinectedin Approval
[2] Zepzelca Prescribing Information
[3] J Clin Oncol - Ovarian Cancer Activity
[4] ClinicalTrials.gov Search: Lurbinectedin Ovarian
[5] FDA.gov - Avelumab Approval
[6] DrugPatentWatch.com - Zepzelca Patents